Avior Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $421K | Buy |
2,658
+819
| +45% | +$111K | 0.01% | 560 |
|
|
2026
Q1 | $235K | Buy |
+1,839
| New | +$230K | 0.01% | 751 |
|
|
2025
Q1 | – | Sell |
-385
| Closed | -$34.7K | – | 2366 |
|
|
2024
Q4 | $34.7K | Buy |
385
+307
| +394% | +$29.7K | ﹤0.01% | 1263 |
|
|
2024
Q3 | $7.71K | Hold |
78
| – | – | ﹤0.01% | 1632 |
|
|
2024
Q2 | $7.23K | Sell |
78
-260
| -77% | -$23.3K | ﹤0.01% | 1607 |
|
|
2024
Q1 | $32.1K | Buy |
338
+323
| +2,153% | +$30K | ﹤0.01% | 1410 |
|
|
2023
Q4 | $1.34K | Hold |
15
| – | – | ﹤0.01% | 1350 |
|
|
2023
Q3 | $1.09K | Hold |
15
| – | – | ﹤0.01% | 1439 |
|
|
2023
Q2 | $1.25K | Hold |
15
| – | – | ﹤0.01% | 1401 |
|
|
2023
Q1 | $1.14K | Hold |
15
| – | – | ﹤0.01% | 1449 |
|
|
2022
Q4 | $1.25K | Hold |
15
| – | – | ﹤0.01% | 1099 |
|
|
2022
Q3 | $1K | Hold |
15
| – | – | ﹤0.01% | 1117 |
|
|
2022
Q2 | $1K | Sell |
15
-250
| -94% | -$18.8K | ﹤0.01% | 1033 |
|
|
2022
Q1 | $23K | Buy |
265
+200
| +308% | +$18.5K | ﹤0.01% | 691 |
|
|
2021
Q4 | $7K | Hold |
65
| – | – | ﹤0.01% | 850 |
|
|
2021
Q3 | $8K | Hold |
65
| – | – | ﹤0.01% | 802 |
|
|
2021
Q2 | $8K | Hold |
65
| – | – | ﹤0.01% | 784 |
|
|
2021
Q1 | $8K | Hold |
65
| – | – | ﹤0.01% | 791 |
|
|
2020
Q4 | $9K | Hold |
65
| – | – | ﹤0.01% | 732 |
|
|
2020
Q3 | $7K | Hold |
65
| – | – | ﹤0.01% | 727 |
|
|
2020
Q2 | $7K | Buy |
65
+15
| +30% | +$1.48K | ﹤0.01% | 704 |
|
|
2020
Q1 | $3K | Hold |
50
| – | – | ﹤0.01% | 672 |
|
|
2019
Q4 | $4K | Hold |
50
| – | – | ﹤0.01% | 680 |
|
|
2019
Q3 | $3K | Hold |
50
| – | – | ﹤0.01% | 665 |
|
|
2019
Q2 | $4K | Hold |
50
| – | – | ﹤0.01% | 685 |
|
|
2019
Q1 | $4K | Sell |
50
-1,206
| -96% | -$103K | ﹤0.01% | 588 |
|
|
2018
Q4 | $90K | Sell |
1,256
-412
| -25% | -$33.2K | 0.02% | 441 |
|
|
2018
Q3 | $160K | Sell |
1,668
-217
| -12% | -$21K | 0.03% | 387 |
|
|
2018
Q2 | $179K | Buy |
1,885
+54
| +3% | +$4.96K | 0.04% | 351 |
|
|
2018
Q1 | $161K | Sell |
1,831
-124
| -6% | -$11.3K | 0.04% | 365 |
|
|
2017
Q4 | $166K | Buy |
+1,955
| New | +$164K | 0.04% | 378 |
|
|
2017
Q2 | – | Sell |
-100
| Closed | -$7K | – | 500 |
|
|
2017
Q1 | $7K | Buy |
+100
| New | +$6.72K | ﹤0.01% | 392 |
|
Other funds holding XBI
JFG
Avior Wealth Management's XBI Position: Q2 2026 in Review
Avior Wealth Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 45% in Q2 2026, buying an estimated $111K and bringing the position to 2,658 shares worth $421K. The position accounts for 0.01% of the portfolio, ranked #560.
Avior Wealth Management first reported a position in XBI in Q1 2017 and has held it in 32 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Avior Wealth Management held 2,658 shares of State Street SPDR S&P Biotech ETF worth $421K as of Q2 2026.
- Avior Wealth Management bought 819 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $111K.
- State Street SPDR S&P Biotech ETF made up 0.01% of Avior Wealth Management's portfolio in Q2 2026, its #560 holding.
- Avior Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 32 quarters since.
- 932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Avior Wealth Management's 13F filing for Q2 2026, filed 7 Jul 2026.